Bibliography
- Mizrahi M , IlanY: The gut mucosa as a site for induction of regulatory T-cells.Curr. Pharm. Des.15(11) 1191–1202 (2009).
- Harrington LE , HattonRD, ManganPR et al.: Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages.Nat. Immunol.6 , 1123–1132 (2005).
- Zheng SG , WangJ, HorwitzDA: FoxP3+CD4+CD25+ regulatory T cells induced by IL-2 and TFG-β are resistant to Th17 conversion by IL-6.J. Immunol.1180(11) , 7112–7116 (2008).
- Boden EK , SnapperSB: Regulatory T cells in inflammatory bowel disease.Curr. Opin. Gastroenterol.24(6) , 733–741 (2008).
- Gil-Guerrero L , DotorJ, HuibregtseIL et al.: In vitro and in vivo down-regulation of regulatory T cell activity with a peptide inhibitor of TGF-β1.J. Immunol.181(1) , 126–135 (2008).
- Baumgart DC , CardingSR: Inflammatory bowel disease: cause and immunobiology.Lancet369 , 1627–1640 (2007).
- Cho JH : The genetics and immunopathogenesis of inflammatory bowel disease.Nat. Rev. Immunol.8(6) , 458–466 (2008).
- Mizoguchi A , MizoguchiE: Inflammatory bowel disease, past, present and future: lessons from animal models.J. Gastroenterol.43 , 1–17 (2008).
- Eastaff-Leung N : FoxP3+ regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease.J. Clin. Immunol.30(1) , 80–89 (2010).
- Earle KE , TangQ, ZhouX et al.: In vitro expanded human CD4+CD25+ regulatory T cells suppress effector T cell proliferation.Clin. Immunol.115 , 3–9 (2005).
- Allan SE , AlstadAN, MerindolN et al.: Generation of potent and stable human CD4+ T regulatory cells by activation-independent expression of FOXP3.Mol. Ther.16 , 194–202 (2008).
- Huter EN , PunkosdyGA, GlassDD et al.: TGF-β-induced FoxP3+ regulatory T cells rescue scurfy mice.Eur. J. Immunol.38 , 1814–1821 (2008).
- Ding Y , ShenS, LinoAC et al.: β-catenin stabilization extends regulatory T cell survival and induces anergy in nonregulatory T cells.Nat. Med.14 , 162–169 (2008).
- Hill DA , ArtisD: Intestinal bacteria and the regulation of immune cell homeostasis.Annu. Rev. Immunol.28 , 623–667 (2010).
- Braat H , van den Brande J, van Tol E, Hommes D, Peppelenbosch M, van Deventer S: Lactobacillus rhamnosus induces peripheral hyporesponsiveness in stimulated CD4+ T cells via modulation of dendritic cell function. Am. J. Clin. Nutr.80(6) , 1618–1625 (2004).
- Fedorak RN : Understanding why probiotic therapies can be effective in treating IBDJ. Clin. Gastroenterol.42(Suppl. 3) , Pt 1, S111–S115 (2008).
- Williams CA , HarryRA, McLeodJD: Apoptotic cells induce dendritic cell-mediated suppression via interferon-γ-induced IDO.Immunology124(1) , 89–101 (2008).
- You S , CandonS, KuhnC, BachJF, ChatenoudL: CD3 antibodies as unique tools to restore self-tolerance in established autoimmunity their mode of action and clinical application in Type 1 diabetes.Adv. Immunol.100 , 13–37 (2008).
- Korn T , BettelliE, OukkaM, KuchrooVK: IL-17 and Th17 cells.Annu. Rev. Immunol.27 , 485–517 (2009).
- Ito H , TakazoeM, FukudaY et al.: A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn‘s disease.Gastroenterology126 , 989–996 (2004).
- Lindsay J , Van Montfrans C, Brennan F et al.: IL-10 gene therapy prevents TNBS-induced colitis. Gene Ther.9(24) , 1715–1721 (2002).
- Barbara G , XingZ, HogaboamCM, GauldieJ, CollinsSM: Interleukin 10 gene transfer prevents experimental colitis in rats.Gut46(3) , 344–349 (2000).
- Lindsay JO , CiesielskiCJ, ScheininT, HodgsonHJ, BrennanFM: The prevention and treatment of murine colitis using gene therapy with adenoviral vectors encoding IL-10.J. Immunol.166(12) , 7625–7633 (2001).
- Engel MA , NeurathMF: New pathophysiological insights and modern treatment of IBD.J. Gastroenterol.45(6) , 571–583 (2010).
- Kristensen NN , ClaessonMH: Future targets for immune therapy in colitis?Endocr. Metab. Immune Disord. Drug Targets8(4) , 295–300 (2008).